Selected research
Market Structure
Global GLP-1 Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global GLP-1 Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for GLP-1 Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for GLP-1 Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for GLP-1 Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for GLP-1 Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of GLP-1 Injection include Zhengda Tianqing, Innovent Biologics, Wanbang Biopharma, Sihuan Pharmaceuticals, CSPC Pharmaceutical Group, Shanghai Benemae Biopharmaceuticals Co., Ltd., Pegbio, Eli Lilly and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
On the production side, the report examines GLP-1 Injection output, growth rates, and market shares by manufacturer and by region (at regional and country level) for 2021-2026, with forecasts through 2032.
On the consumption side, the report analyzes sales of GLP-1 Injection by region (regional and country level), company, type, and application for 2021-2026 and provides forecasts through 2032.
The report provides an overview of the global GLP-1 Injection market in terms of capacity, output, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of GLP-1 Injection and consumption patterns in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents GLP-1 Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by type and application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Injection market size, projected growth trends, production technologies, key applications, and end-use industries.
GLP-1 Injection Segment by Company
Zhengda Tianqing
Innovent Biologics
Wanbang Biopharma
Sihuan Pharmaceuticals
CSPC Pharmaceutical Group
Shanghai Benemae Biopharmaceuticals Co., Ltd.
Pegbio
Eli Lilly
Huadong Medicine
Hongyun Huaning
Hengrui Medicine
Hansoh Pharmaceuticals
Gan & Lee Pharmaceuticals
Borui Pharmaceuticals
Imeik
Novo Nordisk
GLP-1 Injection Segment by Type
Benaglutide
Liraglutide
Semaglutide
Tirzepatide
Others
GLP-1 Injection Segment by Application
Diabetes
Obesity
Others
GLP-1 Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the GLP-1 Injection market, including product definition, global market growth prospects, production value, capacity, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Injection industry.
Chapter 3: Detailed analysis of GLP-1 Injection market competition landscape. Including GLP-1 Injection manufacturers' output value, output and average price from 2021 to 2026, as well as competition analysis indicators such as origin, product type, application, merger and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 7: Production/Production Value of GLP-1 Injection by region. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 8: Consumption of GLP-1 Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Benaglutide
- Liraglutide
- Semaglutide
- Tirzepatide
- Others
Applications
- Diabetes
- Obesity
- Others
Companies covered
- Zhengda Tianqing
- Innovent Biologics
- Wanbang Biopharma
- Sihuan Pharmaceuticals
- CSPC Pharmaceutical Group
- Shanghai Benemae Biopharmaceuticals Co., Ltd.
- Pegbio
- Eli Lilly
- Huadong Medicine
- Hongyun Huaning
- Hengrui Medicine
- Hansoh Pharmaceuticals
- Gan & Lee Pharmaceuticals
- Borui Pharmaceuticals
- Imeik
- Novo Nordisk
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global GLP-1 Injection Production Value Estimates and Forecasts (2021-2032)
- 1.2.2 Global GLP-1 Injection Production Capacity Estimates and Forecasts (2021-2032)
- 1.2.3 Global GLP-1 Injection Production Estimates and Forecasts (2021-2032)
- 1.2.4 Global GLP-1 Injection Market Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Global GLP-1 Injection Market Dynamics
- 2.1 GLP-1 Injection Industry Trends
- 2.2 GLP-1 Injection Industry Drivers
- 2.3 GLP-1 Injection Industry Opportunities and Challenges
- 2.4 GLP-1 Injection Industry Restraints
3 GLP-1 Injection Market by Manufacturers
- 3.1 Global GLP-1 Injection Production Value by Manufacturers (2021-2026)
- 3.2 Global GLP-1 Injection Production by Manufacturers (2021-2026)
- 3.3 Global GLP-1 Injection Average Price by Manufacturers (2021-2026)
- 3.4 Global GLP-1 Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global GLP-1 Injection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global GLP-1 Injection Manufacturers, Product Type & Application
- 3.7 Global GLP-1 Injection Manufacturers Established Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global GLP-1 Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 GLP-1 Injection Players Market Share by Production Value in 2025
- 3.8.3 2025 GLP-1 Injection Tier 1, Tier 2, and Tier 3
4 GLP-1 Injection Market by Type
- 4.1 GLP-1 Injection Type Introduction
- 4.1.1 Benaglutide
- 4.1.2 Liraglutide
- 4.1.3 Semaglutide
- 4.1.4 Tirzepatide
- 4.1.5 Others
- 4.2 Global GLP-1 Injection Production by Type
- 4.2.1 Global GLP-1 Injection Production by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global GLP-1 Injection Production by Type (2021-2032)
- 4.2.3 Global GLP-1 Injection Production Market Share by Type (2021-2032)
- 4.3 Global GLP-1 Injection Production Value by Type
- 4.3.1 Global GLP-1 Injection Production Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global GLP-1 Injection Production Value by Type (2021-2032)
- 4.3.3 Global GLP-1 Injection Production Value Market Share by Type (2021-2032)
5 GLP-1 Injection Market by Application
- 5.1 GLP-1 Injection Application Introduction
- 5.1.1 Diabetes
- 5.1.2 Obesity
- 5.1.3 Others
- 5.2 Global GLP-1 Injection Production by Application
- 5.2.1 Global GLP-1 Injection Production by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global GLP-1 Injection Production by Application (2021-2032)
- 5.2.3 Global GLP-1 Injection Production Market Share by Application (2021-2032)
- 5.3 Global GLP-1 Injection Production Value by Application
- 5.3.1 Global GLP-1 Injection Production Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global GLP-1 Injection Production Value by Application (2021-2032)
- 5.3.3 Global GLP-1 Injection Production Value Market Share by Application (2021-2032)
6 Company Profiles
- 6.1 Zhengda Tianqing
- 6.1.1 Zhengda Tianqing Company Information
- 6.1.2 Zhengda Tianqing Business Overview
- 6.1.3 Zhengda Tianqing GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.1.4 Zhengda Tianqing GLP-1 Injection Product Portfolio
- 6.1.5 Zhengda Tianqing Recent Developments
- 6.2 Innovent Biologics
- 6.2.1 Innovent Biologics Company Information
- 6.2.2 Innovent Biologics Business Overview
- 6.2.3 Innovent Biologics GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.2.4 Innovent Biologics GLP-1 Injection Product Portfolio
- 6.2.5 Innovent Biologics Recent Developments
- 6.3 Wanbang Biopharma
- 6.3.1 Wanbang Biopharma Company Information
- 6.3.2 Wanbang Biopharma Business Overview
- 6.3.3 Wanbang Biopharma GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.3.4 Wanbang Biopharma GLP-1 Injection Product Portfolio
- 6.3.5 Wanbang Biopharma Recent Developments
- 6.4 Sihuan Pharmaceuticals
- 6.4.1 Sihuan Pharmaceuticals Company Information
- 6.4.2 Sihuan Pharmaceuticals Business Overview
- 6.4.3 Sihuan Pharmaceuticals GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.4.4 Sihuan Pharmaceuticals GLP-1 Injection Product Portfolio
- 6.4.5 Sihuan Pharmaceuticals Recent Developments
- 6.5 CSPC Pharmaceutical Group
- 6.5.1 CSPC Pharmaceutical Group Company Information
- 6.5.2 CSPC Pharmaceutical Group Business Overview
- 6.5.3 CSPC Pharmaceutical Group GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.5.4 CSPC Pharmaceutical Group GLP-1 Injection Product Portfolio
- 6.5.5 CSPC Pharmaceutical Group Recent Developments
- 6.6 Shanghai Benemae Biopharmaceuticals Co., Ltd.
- 6.6.1 Shanghai Benemae Biopharmaceuticals Co., Ltd. Company Information
- 6.6.2 Shanghai Benemae Biopharmaceuticals Co., Ltd. Business Overview
- 6.6.3 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.6.4 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Injection Product Portfolio
- 6.6.5 Shanghai Benemae Biopharmaceuticals Co., Ltd. Recent Developments
- 6.7 Pegbio
- 6.7.1 Pegbio Company Information
- 6.7.2 Pegbio Business Overview
- 6.7.3 Pegbio GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.7.4 Pegbio GLP-1 Injection Product Portfolio
- 6.7.5 Pegbio Recent Developments
- 6.8 Eli Lilly
- 6.8.1 Eli Lilly Company Information
- 6.8.2 Eli Lilly Business Overview
- 6.8.3 Eli Lilly GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.8.4 Eli Lilly GLP-1 Injection Product Portfolio
- 6.8.5 Eli Lilly Recent Developments
- 6.9 Huadong Medicine
- 6.9.1 Huadong Medicine Company Information
- 6.9.2 Huadong Medicine Business Overview
- 6.9.3 Huadong Medicine GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.9.4 Huadong Medicine GLP-1 Injection Product Portfolio
- 6.9.5 Huadong Medicine Recent Developments
- 6.10 Hongyun Huaning
- 6.10.1 Hongyun Huaning Company Information
- 6.10.2 Hongyun Huaning Business Overview
- 6.10.3 Hongyun Huaning GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.10.4 Hongyun Huaning GLP-1 Injection Product Portfolio
- 6.10.5 Hongyun Huaning Recent Developments
- 6.11 Hengrui Medicine
- 6.11.1 Hengrui Medicine Company Information
- 6.11.2 Hengrui Medicine Business Overview
- 6.11.3 Hengrui Medicine GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.11.4 Hengrui Medicine GLP-1 Injection Product Portfolio
- 6.11.5 Hengrui Medicine Recent Developments
- 6.12 Hansoh Pharmaceuticals
- 6.12.1 Hansoh Pharmaceuticals Company Information
- 6.12.2 Hansoh Pharmaceuticals Business Overview
- 6.12.3 Hansoh Pharmaceuticals GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.12.4 Hansoh Pharmaceuticals GLP-1 Injection Product Portfolio
- 6.12.5 Hansoh Pharmaceuticals Recent Developments
- 6.13 Gan & Lee Pharmaceuticals
- 6.13.1 Gan & Lee Pharmaceuticals Company Information
- 6.13.2 Gan & Lee Pharmaceuticals Business Overview
- 6.13.3 Gan & Lee Pharmaceuticals GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.13.4 Gan & Lee Pharmaceuticals GLP-1 Injection Product Portfolio
- 6.13.5 Gan & Lee Pharmaceuticals Recent Developments
- 6.14 Borui Pharmaceuticals
- 6.14.1 Borui Pharmaceuticals Company Information
- 6.14.2 Borui Pharmaceuticals Business Overview
- 6.14.3 Borui Pharmaceuticals GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.14.4 Borui Pharmaceuticals GLP-1 Injection Product Portfolio
- 6.14.5 Borui Pharmaceuticals Recent Developments
- 6.15 Imeik
- 6.15.1 Imeik Company Information
- 6.15.2 Imeik Business Overview
- 6.15.3 Imeik GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.15.4 Imeik GLP-1 Injection Product Portfolio
- 6.15.5 Imeik Recent Developments
- 6.16 Novo Nordisk
- 6.16.1 Novo Nordisk Company Information
- 6.16.2 Novo Nordisk Business Overview
- 6.16.3 Novo Nordisk GLP-1 Injection Production, Value and Gross Margin (2021-2026)
- 6.16.4 Novo Nordisk GLP-1 Injection Product Portfolio
- 6.16.5 Novo Nordisk Recent Developments
7 Global GLP-1 Injection Production by Region
- 7.1 Global GLP-1 Injection Production by Region: 2021 VS 2025 VS 2032
- 7.2 Global GLP-1 Injection Production by Region (2021-2032)
- 7.2.1 Global GLP-1 Injection Production by Region (2021-2026)
- 7.2.2 Global GLP-1 Injection Production Forecast by Region (2027-2032)
- 7.3 Global GLP-1 Injection Production by Region: 2021 VS 2025 VS 2032
- 7.4 Global GLP-1 Injection Production Value by Region (2021-2032)
- 7.4.1 Global GLP-1 Injection Production Value by Region (2021-2026)
- 7.4.2 Global GLP-1 Injection Production Value by Region (2027-2032)
- 7.5 Global GLP-1 Injection Market Price Analysis by Region (2021-2032)
- 7.6 Regional Production Value Trends (2021-2032)
- 7.6.1 North America GLP-1 Injection Production Value (2021-2032)
- 7.6.2 Europe GLP-1 Injection Production Value (2021-2032)
- 7.6.3 Asia-Pacific GLP-1 Injection Production Value (2021-2032)
- 7.6.4 South America GLP-1 Injection Production Value (2021-2032)
- 7.6.5 Middle East & Africa GLP-1 Injection Production Value (2021-2032)
8 Global GLP-1 Injection Consumption by Region
- 8.1 Global GLP-1 Injection Consumption by Region: 2021 VS 2025 VS 2032
- 8.2 Global GLP-1 Injection Consumption by Region (2021-2032)
- 8.2.1 Global GLP-1 Injection Consumption by Region (2021-2026)
- 8.2.2 Global GLP-1 Injection Consumption by Region (2027-2032)
- 8.3 North America
- 8.3.1 North America GLP-1 Injection Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3.2 North America GLP-1 Injection Consumption by Country (2021-2032)
- 8.3.3 U.S.
- 8.3.4 Canada
- 8.3.5 Mexico
- 8.4 Europe
- 8.4.1 Europe GLP-1 Injection Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.4.2 Europe GLP-1 Injection Consumption by Country (2021-2032)
- 8.4.3 Germany
- 8.4.4 France
- 8.4.5 U.K.
- 8.4.6 Italy
- 8.4.7 Netherlands
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific GLP-1 Injection Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.5.2 Asia Pacific GLP-1 Injection Consumption by Country (2021-2032)
- 8.5.3 China
- 8.5.4 Japan
- 8.5.5 South Korea
- 8.5.6 Southeast Asia
- 8.5.7 India
- 8.5.8 Australia
- 8.6 South America
- 8.6.1 South America GLP-1 Injection Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.6.2 South America GLP-1 Injection Consumption by Country (2021-2032)
- 8.6.3 Brazil
- 8.6.4 Argentina
- 8.6.5 Chile
- 8.6.6 Colombia
- 8.7 Middle East & Africa
- 8.7.1 Middle East & Africa GLP-1 Injection Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.7.2 Middle East & Africa GLP-1 Injection Consumption by Country (2021-2032)
- 8.7.3 Egypt
- 8.7.4 South Africa
- 8.7.5 Israel
- 8.7.6 Türkiye
- 8.7.7 GCC Countries
9 Value Chain and Sales Channels Analysis
- 9.1 GLP-1 Injection Value Chain Analysis
- 9.1.1 GLP-1 Injection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 GLP-1 Injection Production Mode & Process
- 9.2 GLP-1 Injection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 GLP-1 Injection Distributors
- 9.2.3 GLP-1 Injection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst